I am a
Home I AM A Search Login

Papers of the Week

2019 May/Jun

J Clin Psychopharmacol



A Long-Term, Open-label Study to Evaluate the Safety and Tolerability of Brexpiprazole as Adjunctive Therapy in Adults With Major Depressive Disorder.


Hobart M, Zhang P, Skuban A, Brewer C, Hefting N, Sanchez R, McQuade RD
J Clin Psychopharmacol. 2019 May/Jun; 39(3):203-209.
PMID: 30946704.


Long-term treatment is recommended in major depressive disorder (MDD) to prevent relapse and to restore functioning. The aim of this study (Orion; NCT01360866) was to assess the long-term safety, tolerability, and efficacy of open-label treatment with adjunctive brexpiprazole in adult patients with MDD.